Cumberland Pharmaceuticals Inc. (CPIX) - 2025 Annual Report Summary
Business Context and Reporting Period
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription drugs. The company targets hospital acute care, gastroenterology, and oncology markets. This summary covers the fiscal year ended December 31, 2025.
The company's portfolio includes seven FDA-approved brands: Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ, and Talicia. In 2025, the company expanded its portfolio by entering a co-commercialization agreement for Talicia and advanced its clinical pipeline, specifically the ifetroban candidate for Duchenne muscular dystrophy (DMD).
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Net Revenues | $44.5 million | $37.9 million |
| Net Loss | $(2.9) million | $(6.4) million |
| Operating Loss | $(2.8) million | $(6.4) million |
| Gross Margin | 85.0% | 82.6% |
| Cash and Cash Equivalents | $11.4 million | $18.0 million |
| Working Capital | $0.3 million | $4.8 million |
| Debt (Revolving Credit Facility) | $5.2 million outstanding | $15.3 million outstanding |
| Operating Cash Flow | $4.9 million | $(0.6) million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased by 17.6% ($6.7 million) year-over-year, driven by growth in Sancuso (+32%), Vibativ (+32%), and the addition of Talicia ($3.3 million).
- Product Performance:
- Sancuso: Revenue rose to $11.9 million due to increased shipments and improved product returns.
- Vibativ: Revenue increased to $9.5 million, aided by a new 4-vial presentation and expanded access via group purchasing agreements.
- Kristalose: Revenue declined to $10.5 million (from $15.3 million) due to increased generic substitution.
- Vaprisol: No revenue was generated in 2025 as the company is out of commercial inventory pending FDA approval of a new manufacturing facility.
- Profitability: The net loss narrowed significantly from $6.4 million in 2024 to $2.9 million in 2025, primarily due to revenue growth and a reduction in amortization expense.
- Liquidity: Cash and cash equivalents decreased by $6.5 million. This was driven by financing activities (repayment of $10 million on the line of credit) and investing activities ($2.0 million investment in Talicia and $2.5 million for the Kindos project), partially offset by $5.3 million in proceeds from an At-The-Market (ATM) equity offering.
Guidance, Outlook, and Risks
Outlook and Pipeline:
- Ifetroban: The company announced positive Phase II results for ifetroban in DMD-associated cardiomyopathy, showing a statistically significant improvement in left ventricular ejection fraction. Fast Track Designation was granted in February 2026. Phase II studies for Systemic Sclerosis and Idiopathic Pulmonary Fibrosis are ongoing.
- Talicia: The company is co-commercializing Talicia with RedHill Biopharma, assuming U.S. distribution responsibilities.
- Manufacturing: The company is working to resolve FDA Form 483 issues at the new Vaprisol manufacturing facility to resume commercial supply.
Risks and Contingencies:
- Supply Chain: Continued reliance on third-party manufacturers poses risks; Vaprisol remains unavailable until FDA clearance is obtained.
- Competition: Kristalose faces pressure from generic crystalline lactulose products. Acetadote faces competition from generic versions containing EDTA, though the company holds patents on its EDTA-free formulation.
- Debt Covenants: The company must maintain a Minimum Fixed Charge Coverage Ratio under its Revolving Credit Agreement. Failure to comply could trigger a default.
- Regulatory: Changes in healthcare legislation and reimbursement policies (e.g., Medicare negotiation) could impact pricing and revenue.
Investor Verification Checklist
- Vaprisol Relaunch Timeline: Verify the status of the FDA Form 483 resolution at the new manufacturing facility and the expected date for commercial supply resumption.
- Talicia Commercialization: Monitor the financial performance and market penetration of Talicia following the Q4 2025 launch and the $2 million annual investment commitment.
- Ifetroban Regulatory Path: Track the outcomes of the End-of-Phase 2 and Type C meetings with the FDA to determine the timeline for potential Phase 3 trials or NDA submission.
- Debt Covenant Compliance: Review quarterly filings to ensure continued compliance with the Minimum Fixed Charge Coverage Ratio and Borrowing Base Requirements.
- Kristalose Market Share: Assess the effectiveness of initiatives to mitigate generic substitution rates for Kristalose.